循環器ジャーナル67巻1号

2019年01月発行

特集 循環器の現場からの検証：そのエビデンスを日本で活用するには？ Ⅱ．予防医療

わが国でコレステロール値はどこまで下げるか—IMPROVE-ITやFOURIER/ODYSSEY試験の現実的な解釈を巡って

著者： 多田隼人¹

所属機関： ¹金沢大学附属病院循環器内科

ページ範囲：P.42 - P.50

Point
・ランダム化比較試験（RCT）の解釈に当たり，遺伝学的研究結果が大いに参考になりうる．
・The lower，the betterの概念は著明な低値（LDLコレステロール値が数mg/dl程度）までに適応され得ると思われる．
・新規薬剤のより良い適応症例を見極める努力が肝要となる．

参考文献

1) Tarugi P, Averna M, Di Leo E, et al:Molecular diagnosis of hypobetalipoproteinemia:an ENID review. Atherosclerosis 195:e19-27, 2007

2) Raal FJ, Santos RD, Blom DJ, et al:Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia:a randomised, double-blind, placebo-controlled trial. Lancet 375:998-1006, 2010

3) Cuchel M, Bloedon LT, Szapary PO, et al:Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356:148-156, 2007

4) Tada H, Kawashiri MA, Yamagishi M:Do We Expect Any Pleiotropic Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition for Reducing Cardiovascular Events Beyond Low-Density Lipoprotein Cholesterol Reduction? Circ J 81:1098-1099, 2017

5) Giugliano RP, Pedersen TR, Park JG, et al:Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab:a prespecified secondary analysis of the FOURIER trial. Lancet 390:1962-1971, 2017

6) Tada H, Kawashiri MA, Okada H, et al:Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol 115:724-729, 2015

7) Tada H, Kawashiri MA, Nohara A, et al:Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J 38:1573-1579, 2017

8) Tada H, Kawashiri MA, Nohara A, et al:Assessment of arterial stiffness in patients with familial hypercholesterolemia. J Clin Lipidol. 2018 in press

9) Cholesterol Treatment Trialists'（CTT）Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 376:1670-1681, 2010

10) Tada H, Melander O, Louie JZ, et al:Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J 37:561-567, 2016

11) Mega JL, Stitziel NO, Smith JG, et al:Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy:an analysis of primary and secondary prevention trials. Lancet 385:2264-2271, 2015

12) Bonaca MP, Nault P, Giugliano RP, et al:Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease:Insights From the FOURIER Trial（Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk）. Circulation 137:338-350, 2018

13) Giugliano RP, Cannon CP, Blazing MA, et al:Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes:Results from IMPROVE-IT. Circulation 2018, in press

14) Taguchi I, Iimuro S, Iwata H, et al:High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease（REAL-CAD）:A Randomized Superiority Trial. Circulation 137:1997-2009, 2018

15) Itoh H, Komuro I, Takeuchi M, et al:Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy:Report of a Randomized Study. Diabetes Care 2018, in press

16) Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al:Low-density lipoprotein cholesterol targeting with pitavastatin＋ezetimibe for patients with acute coronary syndrome and dyslipidaemia:the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart 38:2264-2276, 2017

17) Tada H, Kawashiri MA, Takata M, et al:Infantile Cases of Sitosterolaemia with Novel Mutations in the ABCG5 Gene:Extreme Hypercholesterolaemia is Exacerbated by Breastfeeding. JIMD Rep 21:115-122, 2015

18) Tada H, Kawashiri MA, Yamagishi M:Comprehensive genotyping in dyslipidemia:mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. J Hum Genet 62:453-458, 2017